CD Biosynsis offers specialized Chlamydomonas reinhardtii CRISPR Interference (CRISPRi) Services, providing a powerful, non-mutagenic platform for tunable gene knockdown. While traditional knockouts are ideal for complete loss-of-function, many genes in Chlamydomonas—especially those involved in photosynthesis, the central cell cycle, and essential metabolic nodes—are lethal when fully deleted. Our CRISPRi platform utilizes a catalytically "dead" Cas9 (dCas9) fused to transcriptional repressors to sterically block RNA polymerase or modify local chromatin, effectively silencing or dampening target gene expression. This reversible and titratable approach is essential for dissecting complex regulatory networks and identifying metabolic bottlenecks in this premier model alga.
Get a QuoteCRISPRi represents a significant advancement over traditional RNAi in Chlamydomonas, which often suffers from inconsistent knockdown levels and off-target effects. By targeting the dCas9 complex to the Transcription Start Site (TSS) or the promoter region, we can achieve high-specificity repression at the DNA level. This method allows researchers to study the dose-dependent effects of gene expression, which is critical for balancing metabolic flux in biofuel production or investigating the quantitative requirements of photosynthetic proteins. Our services ensure stable dCas9 expression and optimized guide RNA (gRNA) design to overcome the high GC-content and complex chromatin structure of the algal nucleus.
We provide multiple CRISPRi configurations designed to maximize repression efficiency while maintaining cell health.
Strong Algal Promoters
Utilizing robust promoters like HSP70-RBCS2 or PSAD to drive dCas9 expression, ensuring continuous repression of target genes throughout the growth cycle.
Epigenetic Fusions
Fusing dCas9 with transcriptional repressors specifically optimized for the Chlamydomonas chromatin environment to enhance the depth of silencing.
Nitrate/Heat-Shock Control
Placing dCas9 under the control of inducible promoters (e.g., NIT1 or HSP70A), allowing researchers to trigger gene repression at specific developmental stages or environmental conditions.
Essential Gene Study
Ideal for studying genes required for viability, where repression can be initiated after the culture has reached a specific density.
Pathway-Scale Silencing
Simultaneous targeting of multiple enzymes in a branched metabolic pathway (e.g., starch vs. lipid biosynthesis) using gRNA arrays to redirect carbon flux.
Redundant Family Targeting
Repressing multiple members of a gene family (e.g., Light-Harvesting Complexes) to observe cumulative phenotypic effects.
1. TSS Mapping & gRNA Design
2. dCas9 Cassette Assembly
3. Transformation & Integration
4. Validation of Knockdown
Precise identification of the Transcription Start Site (TSS) for the target gene. Design of gRNAs targeting the "sweet spot" (typically -50 to +200 bp relative to the TSS) to ensure maximum steric hindrance.
Construction of dCas9 expression vectors featuring algal-codon-optimized dCas9, nuclear localization signals (NLS), and appropriate selection markers (e.g., Paromomycin or Hygromycin).
Quantitative Verification: Measurement of mRNA reduction via RT-qPCR.
Phenotypic Validation: Analysis of target protein levels (Western Blot) and functional consequences (e.g., altered chlorophyll fluorescence or growth rate).
Delivery: Provision of verified knockdown strains and a comprehensive data report.
Study of Essential Genes
Enables the study of genes that cannot be knocked out due to lethality, providing a vital tool for exploring the core biology of photosynthesis and cell division.
Titratable Repression
By varying gRNA targeting positions or promoter strengths, we can achieve different levels of knockdown to identify the threshold of protein function.
High Specificity
Unlike RNAi, which relies on the cell's endogenous processing machinery and can have broad off-targets, CRISPRi is guided by DNA-level targeting with minimal cross-reactivity.
Pathway Engineering
Ideal for complex metabolic engineering where multiple genes need to be downregulated simultaneously to redirect energy into high-value bioproducts.
1. How does CRISPRi differ from RNAi in Chlamydomonas?
RNAi acts at the post-transcriptional level by degrading mRNA, which can be inconsistent in algae. CRISPRi acts at the transcriptional level by blocking the production of mRNA entirely, often resulting in cleaner and more predictable knockdown.
2. Is the gene repression permanent?
As long as the dCas9 and gRNA expression cassettes are maintained in the genome, the repression is stable. However, if an inducible promoter is used, the repression can be turned on or off by changing the media or environmental conditions.
3. What level of knockdown can be expected?
Knockdown efficiency typically ranges from 60% to 95% reduction in mRNA levels, depending on the target gene, gRNA position, and the strength of the promoter driving the CRISPRi components.
4. Can you target chloroplast-encoded genes with CRISPRi?
Standard CRISPRi is designed for nuclear genes. While chloroplast engineering is possible, the machinery for transcriptional repression in the plastid is significantly different and requires a specialized approach.
5. How many genes can be repressed at once?
We can deliver multiple gRNAs targeting different genes in a single transformation, making it possible to repress 2-4 genes simultaneously to manipulate entire metabolic pathways.
6. Do you provide validation of protein-level reduction?
Yes, in addition to RT-qPCR for mRNA quantification, we offer Western Blot services to confirm that the protein levels have been effectively reduced.
7. What is the typical lead time for a CRISPRi project?
A standard project, including design, transformation, and molecular validation, typically takes 14-18 weeks.
8. What information is needed to start a project?
We require the target gene ID or sequence and your desired repression strategy (e.g., constitutive vs. inducible). Our team will handle the TSS mapping and gRNA optimization.
CRISPR-Cas9 technology represents a transformative advancement in gene editing techniques. The main function of the system is to precisely cut DNA sequences by combining guide RNA (gRNA) with the Cas9 protein. This technology became a mainstream genome editing tool quickly after its 2012 introduction because of its efficient, simple and low-cost nature.
The CRISPR gene editing system with its Cas9 version stands as a vital instrument for current biological research. CRISPR technology enables gene knockout (KO) through permanent gene expression blockage achieved by sequence disruption. Various scientific domains including disease modeling and drug screening employ this technology to study gene functions. CRISPR KO technology demonstrates high efficiency and precision but requires confirmation and verification post-implementation because unsatisfactory editing may produce off-target effects or incomplete gene knockouts which impact experimental result reliability. For precise and efficient Gene Editing Services - CD Biosynsis, Biosynsis offers comprehensive solutions tailored to your research needs.
The CRISPR-Cas9 knockout cell line was developed using CRISPR/Cas9 gene editing to allow scientists to remove genes accurately for research on gene function and disease models and pharmaceutical discovery. Genetic research considers this technology essential due to its high efficiency together with simple operation and broad usability.
If your question is not addressed through these resources, you can fill out the online form below and we will answer your question as soon as possible.
CD Biosynsis is a leading customer-focused biotechnology company dedicated to providing high-quality products, comprehensive service packages, and tailored solutions to support and facilitate the applications of synthetic biology in a wide range of areas.